Company Encyclopedia
View More
name
Alltest
688606.SH
Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; fluorescence immunoassay tests and analyzers; urine analysis solutions, biochemistry reagents, VTM, blood glucose monitoring systems, and HB hemoglobin test meters.
349.86 B
688606.SHMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
B
Health Care SuppliesIndustry
Industry Ranking8/41
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.58%B
    • Profit Margin33.43%A
    • Gross Margin55.87%B
  • Growth ScoreC
    • Revenue YoY8.47%B
    • Net Profit YoY6.59%C
    • Total Assets YoY1.86%C
    • Net Assets YoY0.45%C
  • Cash ScoreC
    • Cash Flow Margin299.11%C
    • OCF YoY8.47%B
  • Operating ScoreD
    • Turnover0.21D
  • Debt ScoreA
    • Gearing Ratio8.03%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Alltest plans to distribute a profit of 10 yuan for every 10 shares in the mid-term of 2025

    According to the Zhitong Finance APP, Alltest announced that the company's profit distribution plan for the mid-term of 2025 proposes to distribute a cash dividend of 10 yuan (tax included) for every 10 shares

    Zhitong·
    SH
    688606
    -2.99%
    Zhitong·
    SH
    688606
    -2.99%

    Hangzhou Alltest plans to distribute over 78.3 million yuan in mid-2025

    Hangzhou Alltest Biotechnology Co., Ltd. plans to distribute a cash dividend of 10 yuan for every 10 shares to all shareholders in mid-2025, with an expected total cash distribution amount of over 78.3 million yuan. This distribution plan has been approved by the board of directors and the supervisory board, and does not need to be submitted for shareholder meeting approval, nor will it have a significant impact on the company's operating cash flow

    Zhitong·
    SH
    688606
    -2.99%
    Zhitong·
    SH
    688606
    -2.99%

    The three major A-share indices closed mixed, with the Hainan Free Trade Zone concept leading the decline

    36Kr learned that the three major indices of A-shares closed mixed, with the Shanghai Composite Index up 0.01%, the Shenzhen Component Index down 0.37%, and the ChiNext Index down 0.01%; the Hainan Free Trade Zone, construction machinery, and education sectors led the decline, with HNSS down over 9%, Nan feng Corporation and Sany down over 5%, and OFFCN EDU down over 1%; brokerage firms, internet, and biotechnology sectors strengthened, with GuoXin Securities up over 5%, UCloud and Alltest up over 3%

    36Kr·
    SZ
    002607
    -4.12%
    SZ
    300004
    -3.38%
    SZ
    002320
    -3.92%
    36Kr·
    SZ
    002607
    -4.12%
    SZ
    300004
    -3.38%
    SZ
    002320
    -3.92%

    Alltest Biotech's Unit Buys Land for Planned Factory for 19 Million Yuan

    Hangzhou Alltest Biotech's unit, Fanling Biotechnology (Hangzhou), bought land for 19.2 million yuan, according to a Shanghai bourse filing on Tuesday. The land, with a land area of 21,270 square meters, is located in the Chinese communities of Hengtang and Gongnong. The land will be the site for a factory that will produce 200 million diagnostic reagents and electronic instruments every year. The medical diagnostic company will invest up to 300 million yuan into the project.

    Trading View·
    SH
    688606
    -2.99%
    Trading View·
    SH
    688606
    -2.99%

    Alltest establishes a new supply chain company in Hangzhou

    According to the Qichacha APP, recently, Hangzhou Jiesuda Supply Chain Co., Ltd. was established, with Gao Fei as the legal representative and a registered capital of 1 million yuan. The business scope includes: supply chain management services; customs declaration services; inspection services; import and export of goods; maritime international cargo transportation agency, etc. Qichacha's equity penetration shows that the company is wholly owned by Alltest

    Zhitong·
    SH
    688606
    -2.99%
    Zhitong·
    SH
    688606
    -2.99%